In Y-79 cells, NPS-2143 at 16.5 µM significantly down-regulated p-P65 NF-κB, P65 NF-κB, p-IκBα and IκBα expression compared with control. In HEK293 cells transfected with mutant Gln723 CaSR-EGFP, NPS-2143 treatment yielded higher EC50 values than the matched mutant-plus-vehicle control. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Expression of signaling components in Y-79 cells
Cell-based study · Y-79 cells [1]
Y-79 cells were treated with NPS-2143 at 16.5 µM. Expression of p-P65 NF-κB, P65 NF-κB, p-IκBα and IκBα was significantly down-regulated compared with the control group.
Literature-Reported Treatment Conditions
- Treatment concentration
- 16.5 µM
- Reported limits
- Not stated in the sentences used: route, schedule, vehicle.
Methods and source locations
Compound reported in the paper: NPS-2143
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > NPS-2143 suppressed the proliferation of Y-79 cells and induced the apoptosis of Y-79 cells (S44); Results > NPS-2143 affected the malignant behaviors of Y-79 cells through regulating NF-κB signaling pathway (S55); Fig. 2 legend (S83)
the expression of NF-κB signaling pathway related key genes, p-P65 NF-κB, P65 NF-κB, p-IκBα and IκBα: the expression of NF-κB signaling pathway related key genes, p-P65 NF-κB, P65 NF-κB, p-IκBα and IκBα; comparator: control group — Fig. 2 legend (S83)
Calcium response in transfected HEK293 cells
Cell-based study · HEK293 cells transfected with the mutant Gln723 CaSR-EGFP [2]
HEK293 cells transfected with mutant Gln723 CaSR-EGFP were incubated with NPS-2143 at 20nM, 40nM, and 80nM. EC50 values were 2.79 ±0.19 mM, 3.97 ±0.10 mM, and 4.56 ±0.09 mM, respectively, compared with 1.94 ±0.07 mM for Gln723 (m) plus vehicle.
Literature-Reported Treatment Conditions
- Treatment concentration
- 20nM, 40nM, and 80nM
- Exposure duration
- one hour
- Method
- incubated
- Vehicle
- 15% aqueous solution of 2-hydroxypropyl-β-cyclodextrin
- Co-treatment
- Other interventions in this design: mutant CaSR-EGFP construct; Lipofectamine Plus; Ca2+o 0mM to 10mM. Compound effect isolated by the comparison: Gln723 (m) + vehicle.
Methods and source locations
Compound reported in the paper: NPS-2143
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > In vitro assessment of NPS 2143 on the functional responses of the Leu723Gln mutant CaSR (S1, S3, S5, S9); Materials and Methods > In vivo administration of NPS 2143 to Nuf mice (S13, S14); Figure 2. legend (S48, S50, S53); Table 1. (T1.h1, T1.h2, T1.r2, T1.r3, T1.r4, T1.r5)
EC50 (ie, Ca2+o concentration required for 50% of the maximal response): EC50 (ie, Ca2+o concentration required for 50% of the maximal response); comparator: Gln723 (m) + vehicle — Materials and Methods > In vitro assessment of NPS 2143 on the functional responses of the Leu723Gln mutant CaSR (S9); Table 1. (T1.h1, T1.h2, T1.r2, T1.r3, T1.r4, T1.r5)